To date, intravenous recombinant tissue plasminogen activator (IV-tPA, Alteplase) is the only FDA-approved treatment for AIS, provided that it is administered within 4.5 h following stroke onset [8,9,10]. The gene discussed is PLAT; the disease is androgen insensitivity syndrome.